Allergan (NYSE:AGN) said today that it landed an imported drugs license from the Chinese FDA to market its dexamethasone intravitreal implant, Ozurdex, as a treatment for adults with macular edema following branch retinal vein occlusion or central retinal vein occlusion.
The Dublin-based pharma giant touted its therapy as the first intravitreal injection approved for RVO in China.
Get the full story at our sister site, Drug Delivery Business News.